---
title: "Troglitazone - Diabetes Mellitus Type 2 - 2"
sidebar: mydoc_sidebar
permalink: db00197-mesh-d003924-2.html
toc: false 
---


Path ID: `DB00197_MESH_D003924_2`
{% include image.html url="images/db00197-mesh-d003924-2.png" file="db00197-mesh-d003924-2.png" alt="db00197-mesh-d003924-2" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| DB:DB00197 | Troglitazone | Drug |
| UniProt:P37231 | Peroxisome proliferator-activated receptor gamma (PPAR-gamma) | Protein |
| MESH:D014280 | Triglyceride | ChemicalSubstance |
| MESH:D005227 | Circulating fatty acids | ChemicalSubstance |
| GO:0030073 | Insulin secretion | BiologicalProcess |
| MESH:D001786 | Blood glucose | ChemicalSubstance |
| MESH:D003924 | Diabetes mellitus type 2 | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Troglitazone | INCREASES ACTIVITY OF | Peroxisome Proliferator-Activated Receptor Gamma (Ppar-Gamma) |
| Peroxisome Proliferator-Activated Receptor Gamma (Ppar-Gamma) | DECREASES ABUNDANCE OF | Triglyceride |
| Triglyceride | NEGATIVELY REGULATES | Insulin Secretion |
| Peroxisome Proliferator-Activated Receptor Gamma (Ppar-Gamma) | DECREASES ABUNDANCE OF | Circulating Fatty Acids |
| Circulating Fatty Acids | NEGATIVELY REGULATES | Insulin Secretion |
| Insulin Secretion | DECREASES ABUNDANCE OF | Blood Glucose |
| Blood Glucose | MANIFESTATION OF | Diabetes Mellitus Type 2 |
|---------|-----------|---------|

Comment: Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity

Reference: 
  - [https://go.drugbank.com/drugs/DB00197#mechanismofaction](https://go.drugbank.com/drugs/DB00197#mechanismofaction)
  - DOI:10.18773/austprescr.2004.059
  - [https://pubchem.ncbi.nlm.nih.gov/compound/Troglitazone#section=Pharmacology-and-Biochemistry](https://pubchem.ncbi.nlm.nih.gov/compound/Troglitazone#section=Pharmacology-and-Biochemistry)
